R9Q Stock Chart & Stats
€0.20
€0.00(0.00%)
At close: 4:00 PM EST
€0.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.16 - €0.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€70.38M
Enterprise Value€198.04
Total Cash (Recent Filing)€602.99K
Total Debt (Recent Filing)€11.26M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding299,468,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)€3.18M
Bulls Say, Bears Say
Bulls Say
Pipeline BreadthA diversified clinical-stage pipeline across intravenous, oral and topical formulations for sepsis and skin infections spreads program risk and increases the probability at least one candidate reaches commercialization. This structural breadth supports longer-term franchise potential in antimicrobial resistance markets.
Free Cash Flow ImprovementMaterial FCF growth indicates improving cash generation relative to prior periods and suggests management is beginning to convert activities into positive free cash flow. Over months this reduces near-term funding pressure and can help finance trials or extend runway without immediate equity dilution.
Operational Return EfficiencyA positive ROE implies the company generates returns on the capital base it operates with, reflecting operational efficiency in R&D or resource allocation. While not eliminating balance sheet risks, sustained positive ROE is a durable sign management can extract value from invested resources.
Bears Say
Revenue DeclineA sharp ~22% drop in revenue is a persistent structural concern: declining top line reduces internal funding for clinical programs and increases reliance on external financing. Without revenue stabilization, sustaining multi-stage development programs becomes more challenging over the medium term.
Deep Negative ProfitabilityExtremely negative EBIT and net margins indicate very high cash burn relative to revenues, reflecting steep development and operating expenses. Such structural losses erode flexibility, increase dilution risk, and make long-term program funding contingent on successful clinical milestones or new capital.
Balance Sheet WeaknessNegative equity and a highly negative debt-to-equity ratio signal limited solvency and constrained financial flexibility. Over months this raises refinancing risk, could increase cost of capital, and may limit the company’s ability to fund trials or respond to setbacks without dilutive financing.
Recce Pharmaceuticals Ltd. News
R9Q FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest stock price was €0.16 and its highest was €0.45 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is €70.38M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 42 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 299,468,800 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in DE:R9Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:R9Q Sentiment 75%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.22%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Technical Analysis
Biotron
―
Starpharma Holdings Limited
―
Immuron Limited
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―